Results 51 to 60 of about 88,672,115 (295)

TIM-3 expression in breast cancer

open access: yesOncoImmunology, 2018
Tumor-infiltrating lymphocytes (TILs) are predominantly present in breast cancer patients with estrogen receptor negative tumors, among whom increasing levels correlate with favorable outcomes.
Samantha Burugu   +4 more
doaj   +1 more source

Evidence‐Based Clinical Practice Guidelines for the Management of Pediatric Febrile Neutropenia: Resource‐Sensitive Recommendations for the Asian Continent

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Febrile neutropenia (FN) is a frequent and serious complication in children receiving cancer therapy. Standardizing FN management across Asia is challenging due to variable healthcare infrastructure, diagnostic capacity, and infection patterns; however, it could improve resource use and patient outcomes.
Joliza Patricia Cañeba   +29 more
wiley   +1 more source

LAG

open access: yes, 2023
In a culture that fetishises technology, speed and convenience, painting seems to lag behind. It's accused of being a throwback to our prehistoric, primordial selves; an indulgence in contemporary life and/ or worse - dead.
Anthony Curran (14734669)
core  

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan. Methods Patients who initiated daprodustat between September 2020 and July 2022 were registered.
Tadao Akizawa   +7 more
wiley   +1 more source

The microbiome in human skin aging

open access: yesFEBS Letters, EarlyView.
Age‐related skin changes encompass the well‐known visible phenotypic alterations, together with microbiome dysbiosis and a series of molecular aging hallmarks. These hallmarks characterize not only a fully stablished aged phenotype but also the skin aging process itself.
Manuel Huerta Arana   +3 more
wiley   +1 more source

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy

open access: yesBiomedicines, 2023
One of the most important steps forward in the management of cancer was the discovery of immunotherapy. It has become an essential pillar in the treatment paradigm of cancer patients.
Rebecca Ibrahim   +5 more
doaj   +1 more source

Emerging experimental and computational methods for studying redox‐regulated structural transitions

open access: yesFEBS Letters, EarlyView.
Redox reactions can reshape proteins and alter how they behave in cells, with important consequences for health and disease. This review explores emerging experimental and computational approaches for discovering these redox‐sensitive protein switches, revealing their structural effects, and predicting their behavior, opening new opportunities to ...
Tasneem Rass   +2 more
wiley   +1 more source

Correlations between LAG-3, PD1 and LAG-3+PD1+ expressing CD4 T cells and cardiac function.

open access: yes, 2018
Correlations between LAG-3, PD1 and LAG-3+PD1+ expressing CD4 T cells and cardiac function.
Nagalingeswaran Kumarasamy (36007)   +11 more
core   +1 more source

Prospecting the protein design landscape

open access: yesFEBS Letters, EarlyView.
This review outlines the current state of various protein design approaches. We discuss the current possibilities enabled by recently released tools, highlight future avenues to pursue in protein design, and underscore the crucial role of key databases and resources for successful protein design workflows.
Jakob R. Riccabona   +4 more
wiley   +1 more source

Correlations between LAG-3, PD1 and LAG-3+PD1+ expressing CD8 T cells and cardiac function.

open access: yes, 2018
Correlations between LAG-3, PD1 and LAG-3+PD1+ expressing CD8 T cells and cardiac function.
Nagalingeswaran Kumarasamy (36007)   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy